Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Alteogen (196170) – Hana Securities | Steady Milestone Inflows · Interpreting GSK’s Enhanze Deal · PGR Final Ruling Catalysts / 2026-05-13 Research
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Server Memory Demand · HBM3E Pricing · Margin Expansion / 2026-01-30 Research
  • [Research] Samsung Biologics (207940) – DS Investment & Securities | Plant 5 Revenue Contribution · US Plant Acquisition · Plant 6 Groundbreaking / 2026-04-23 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | HBM4 · Memory Supply Shortage · Shareholder Returns / 2026-01-02 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | Commencing Customer T ESS Business (Estimated) · SDC Asset Utilization · Valuation Gap Narrowing / 2026-02-03 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · HBM Market Share · Earnings Growth / 2026-07-01 Research
  • [Research] Samsung Biologics (207940) – Yuanta Securities | US Site Acquisition · Biosecure Act Beneficiary · Bio Campus 3 Expansion / 2026-04-02 Research
  • [Research] LIG D&A (079550) – Yuanta Securities | 4Q25 Review · Conservative 2026E Guidance · Long-term Structural Growth / 2026-02-19 Research

[Research] LIG D&A (079550) – Shinhan Securities | Structural Export Growth · Order Pipeline · Long-term Demand / 2026-08-07

Posted on August 7, 2026August 21, 2026 By ksb220805@gmail.com

Brokerage : Shinhan Securities

Analyst : Dong-heon Lee, Jihan Lee

Investment Rating : BUY (Maintain)

Target Price : KRW 980,000 (Maintain)

Core Momentum : Structural defense export demand across the Middle East, Europe, and Asia overcoming 2Q earnings variations, backed by a KRW 24.6T backlog and an upgraded 8% OPM guidance

1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: Rating BUY (Maintain), Target Price KRW 980,000 (Maintain), Current Price KRW 702,000 (As of Aug 6, 2026), Upside Potential 39.6%
  • Valuation Methodology: Target price derived by applying a 30% discount to the 2022–2024 peer group average P/E of 42.4x (resulting in a 29.7x target multiple) against the 2027 estimated EPS of KRW 23,504 (slightly adjusted from KRW 24,006)
  • Guidance Upgrade: Full-year corporate operating margin guidance raised from 7% to 8% (reflecting 2H R&D expense expansion)
  • Financial Forecasts & Historicals:
    • 2024: Revenue KRW 3,276.3 Billion, Operating Profit KRW 223.4 Billion, Controlling Net Profit KRW 219.4 Billion, PER 22.1x, ROE 19.4%, PBR 4.0x, EV/EBITDA 15.6x, DY 1.1%
    • 2025: Revenue KRW 4,306.9 Billion, Operating Profit KRW 319.4 Billion, Controlling Net Profit KRW 253.4 Billion, PER 36.6x, ROE 19.2%, PBR 6.5x, EV/EBITDA 23.0x, DY 0.7%
    • 2026F: Revenue KRW 5,227.9 Billion, Operating Profit KRW 487.5 Billion, Controlling Net Profit KRW 378.1 Billion, PER 47.0x, ROE 24.6%, PBR 11.1x, EV/EBITDA 28.7x, DY 0.6%
    • 2027F: Revenue KRW 5,995.5 Billion, Operating Profit KRW 683.3 Billion, Controlling Net Profit KRW 537.7 Billion, PER 34.0x, ROE 29.1%, PBR 8.9x, EV/EBITDA 21.7x, DY 0.8%
    • 2028F: Revenue KRW 6,987.3 Billion, Operating Profit KRW 860.6 Billion, Controlling Net Profit KRW 682.2 Billion, PER 26.8x, ROE 29.6%, PBR 7.1x, EV/EBITDA 18.1x, DY 1.0%
  • Stock Metrics: Market Cap KRW 15,444.0 Billion, Outstanding Shares 22.0 Million shares (Floating Ratio 60.9%), 52-Week High/Low KRW 1,020,000 / KRW 364,500, 60-Day Avg Daily Trading Value KRW 165,826 Million, Foreign Ownership 26.7%, Major Shareholders LIG & 8 affiliated parties (38.2%), National Pension Service (10.3%)

2. [Market Opportunities & Business Outlook]

  • 2Q26 Earnings Review:
    • Consolidated revenue reached KRW 1,110.1 Billion (+17% YoY, -5% QoQ) and operating profit recorded KRW 105.7 Billion (+30% YoY, -38% QoQ, OPM 9.5%), slightly missing consensus (KRW 110.5 Billion operating profit) by 4%.
    • QoQ moderation was driven by normalized delivery schedules following early shipments to the Middle East in 1Q, with no one-off expenses. Ghost Robotics recorded an operating loss of KRW 12.0 Billion.
  • Segment Performance & Order Backlog:
    • 2Q26 Export Revenue: KRW 281.8 Billion (+71% YoY, -31%p QoQ).
    • Domestic Business: R&D revenue KRW 237.7 Billion (+9% YoY, +30% QoQ), Mass production revenue KRW 590.6 Billion (+5% YoY, +2% QoQ).
    • Order Metrics: Order backlog stood at KRW 24.6 Trillion (-3% QoQ), with 2Q new order intake of KRW 326.4 Billion.
  • Market Environment & Export Pipelines:
    • Ongoing geopolitical friction and inventory depletion across the Middle East and Europe sustain robust demand for air defense systems.
    • Deepening defense partnerships across the Asian region.
    • While timing of contract awards entails near-term variability due to extensive ongoing discussions, structural underlying demand continues to expand.

Editor’s Comment (Perspective)

The covering analyst views LIG D&A not as an enterprise constrained by quarterly delivery schedules or temporary shipment pauses following early 1Q fulfillment, but as a structural beneficiary of global air defense inventory depletion across the Middle East, Europe, and Asia. This perspective places primary importance on the substantial KRW 24.6 Trillion order backlog, broadening international pipelines, and the raised full-year OPM guidance of 8%, viewing short-term share price volatility as an attractive entry point.

To verify whether this investment thesis continues to materialize, primary focus should be directed toward the actual execution and timing of export contract awards currently under negotiation, the management of 2H R&D expenditures to secure the full-year 8% OPM target, and the multi-year progression toward 2027–2028 earnings projections (KRW 683.3B OP in 2027F and KRW 860.6B OP in 2028F). These operational milestones can be monitored through upcoming quarterly earnings releases, corporate IR disclosures, contract award filings, and official periodic reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Defense

Post navigation

Previous Post: [Research] LIG D&A (079550) – Eugene Investment & Securities | Global Demand Spillover · CapEx Expansion · Long-term Compounding / 2026-08-07
Next Post: [Research] LIG D&A (079550) – iM Securities | Export Pipeline · CapEx & Hiring Expansion · Global Air Defense Growth / 2026-08-07

Related Posts

  • [Research] Alteogen (196170) – Hana Securities | ALT-B4 Differentiation Potential · Enhanze Biosimilar Concerns Dispelled · Qlex Revenue Visibility / 2026-07-15 Research
  • [Research] LIG D&A (079550) – Hanwha Investment & Securities | 3Q25 Review · Secured Growth Materialization · Expanding Export Share / 2025-11-07 Research
  • [Research] Alteogen (196170) – Hana Securities | New ALT-B4 Deal Signed · Qlex Prescription Surge · SC Conversion Acceleration / 2026-08-06 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | Plant 5 PPQ Revenue · US Site Consolidation · Guidance Revision Potential / 2026-04-23 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Hyperscaler Capex · Custom HBM · Inference Memory Demand / 2026-05-04 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Acquisition Finalized · Guidance Revision Outlook · Tariff Resilience / 2026-04-02 Research
  • [Research] Samsung SDI (006400) – Shinhan Securities | Profit Turnaround · ESS Margin Support · North America LFP Ramp-up / 2026-07-20 Research
  • [Research] Samsung SDI (006400) – Kiwoom Securities | Quarterly Turnaround · ESS LFP Ramp-up · Europe EV Market Share / 2026-07-31 Research
  • [Research] Celltrion (068270) – Yuanta Securities | New Biosimilar Growth · Facility Expansion · CMO Capacity Readiness / 2026-05-07 Research
  • [Research] LIG D&A (079550) – DS Investment & Securities | Order Expansion · Iraq Cheongung-II Mass Production · Long-term Earnings Growth / 2026-08-07 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Capex Discipline · Multi-Year LTA · Shareholder Returns / 2026-01-30 Research
  • [Research] Samsung SDI (006400) – Mirae Asset | North American ESS · European LFP Orders · Market Share Expansion / 2026-08-13 Research
  • [Research] Samsung SDI (006400) – iM Securities | US ESS Market Share Gains · Mid-Term ESS OP of KRW 1.4T · 4Q Loss Narrowing / 2026-02-03 Research
  • [Research] SK hynix (000660 / SKHY) – Hanwha | LTA · HBM · Earnings Sustainability / 2026-04-24 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme